Peer-Reviewed Journal Details
Mandatory Fields
Lambe, T.,Carey, J. B.,Li, Y.,Spencer, A. J.,van Laarhoven, A.,Mullarkey, C. E.,Vrdoljak, A.,Moore, A. C.,Gilbert, S. C.
Sci Rep
Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1
WOS: 54 ()
Optional Fields
Adenoviridae/genetics/*immunology Administration, Intranasal Animals CD8-Positive T-Lymphocytes/cytology/immunology/metabolism Cytokines/metabolism Female Genetic Vectors/genetics/metabolism Immunization, Secondary Influenza Vaccines/biosynthesis/genetics/immunology Influenzavirus A/*immunology/metabolism Injections, Intradermal Interferon-gamma/metabolism Mice Mice, Inbred BALB C Mice, Inbred C57BL Orthomyxoviridae Infections/immunology/prevention & control RNA-Binding Proteins/genetics/metabolism Spleen/cytology/metabolism Vaccinia virus/genetics/*immunology Viral Core Proteins/genetics/metabolism Viral Matrix Proteins/genetics/metabolism
Alternate prime/boost vaccination regimens employing recombinant replication-deficient adenovirus or MVA, expressing Influenza A virus nucleoprotein and matrix protein 1, induced antigen-specific T cell responses in intradermally (ID) vaccinated mice; with the strongest responses resulting from Ad/MVA immunization. In BALB/C mice the immunodominant response was shifted from the previously identified immunodominant epitope to a novel epitope when the antigen was derived from A/Panama/2007/1999 rather than A/PR/8. Alternate immunization routes did not affect the magnitude of antigen-specific systemic IFN-gamma response, but higher CD8(+) T-cell IFN-gamma immune responses were seen in the bronchoalveolar lavage following intransal (IN) boosting after intramuscular (IM) priming, whilst higher splenic antigen-specific CD8(+) T cell IFN-gamma was seen following IM boosting. Partial protection against heterologous influenza virus challenge was achieved following either IM/IM or IM/IN but not ID/ID immunization. These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naive infants.
2045-2322 (Electronic) 20
Grant Details